Early Preview·This tool is in active development. Results may need verification.
SpectralBench
Determine your spectroscopy software's FDA regulatory pathway in 5 questions
Building spectroscopy software for clinical use? The FDA's Software as a Medical Device (SaMD) framework determines whether your software requires regulatory clearance — and which pathway applies. Getting this classification right early saves months of rework and hundreds of thousands in consulting fees.
This interactive wizard walks you through the key questions the FDA considers when classifying SaMD: what your software does with spectral data, the clinical significance of the condition, the intended user, and your spectroscopy modality. In five steps, you'll receive a preliminary classification (Class I, II, or III), the recommended regulatory pathway (510(k), De Novo, or PMA), estimated timelines and costs, and a tailored checklist of next steps.
| Pathway | Timeline | Cost | Risk Class | When Used |
|---|---|---|---|---|
| 510(k) | 6–12 months | $50K–$150K | Class II | Predicate device exists |
| De Novo | 12–18 months | $100K–$300K | Class I/II | No predicate, low-moderate risk |
| PMA | 18–36 months | $300K–$1M+ | Class III | High risk, life-sustaining |
The International Medical Device Regulators Forum (IMDRF) established the global framework that the FDA uses to categorize SaMD risk. The framework evaluates two dimensions: the significance of the information provided by the software (inform, diagnose, or treat) and the state of the healthcare condition (non-serious, serious, or critical).
For spectroscopy-based SaMD, common scenarios include Raman tissue classification for cancer detection (typically Class II–III), FTIR-based pathogen identification (Class II), and NIR monitoring for process analytical technology (often Class I or non-SaMD). The modality itself doesn't determine the class — it's the clinical intent and autonomy of the software that matters.
Understanding this framework early in development lets you design your spectral analysis pipeline with the right level of validation, documentation, and quality controls from the start — rather than retrofitting them before submission.
Spectroscopy SaMD faces unique regulatory challenges. Unlike imaging-based diagnostics with extensive predicate device history, spectroscopic techniques — particularly SERS, terahertz, and multimodal approaches — may have limited or no FDA-cleared predicates. This often pushes novel spectroscopy SaMD toward the De Novo pathway, which, while more time-consuming, establishes your device as the predicate for future competitors.
Key documentation areas for spectroscopy SaMD include analytical validation of your spectral processing algorithms (preprocessing, baseline correction, peak fitting), reproducibility across instruments and operators, and clinical validation against reference methods. The FDA expects you to demonstrate that your peak identification or classification algorithms perform reliably across the range of clinical samples they will encounter.
Software as a Medical Device (SaMD) is software intended to be used for medical purposes without being part of a hardware medical device. The FDA regulates SaMD under a risk-based framework developed by the International Medical Device Regulators Forum (IMDRF). Examples include diagnostic algorithms that analyze spectroscopic data to identify diseases, or software that provides treatment recommendations based on spectral biomarkers.
The FDA classifies SaMD into three risk categories: Class I (lowest risk, general controls), Class II (moderate risk, special controls, typically 510(k) or De Novo), and Class III (highest risk, premarket approval). Classification depends on the significance of the information provided by the software, the seriousness of the healthcare condition, and the level of clinical oversight. Software that only displays data without interpretation is generally not considered SaMD.
The 510(k) pathway requires demonstrating substantial equivalence to an existing cleared device (predicate). De Novo is for novel, low-to-moderate risk devices with no suitable predicate — it creates a new classification. PMA (Premarket Approval) is the most stringent pathway for high-risk Class III devices, requiring clinical trial data. For spectroscopy SaMD, 510(k) is common when predicate devices exist for modalities like FTIR or Raman, while De Novo may be needed for novel techniques like SERS.
It depends on the intended use. Software that acquires, displays, or transfers spectral data without clinical interpretation is generally not SaMD. Software that processes spectral data to inform clinical decisions — such as identifying disease biomarkers, classifying tissue samples, or recommending treatments — likely qualifies as SaMD. The key factor is whether the software's output is intended to drive medical decisions. Use the wizard above to assess your specific situation.
Research Use Only (RUO) products are exempt from FDA premarket review but must be clearly labeled and cannot be marketed for clinical diagnostic use. RUO is appropriate for laboratory research tools that are not intended for clinical decision-making. However, the FDA may challenge an RUO designation if evidence suggests the product is actually being used or promoted for clinical purposes.
Timelines vary significantly by pathway. A 510(k) submission typically takes 6–12 months total (about 90 days of FDA review). De Novo classification takes 12–24 months (about 150 days of FDA review). PMA can take 2–5 years including clinical trials. These timelines include preparation time — the actual FDA review period is shorter, but preparing a complete submission with all required documentation and testing is the major time investment.
A 510(k) submission typically takes 6–12 months from start to FDA clearance. The FDA review itself averages about 90 days (MDUFA review clock), but preparation — identifying a predicate device, compiling performance data, drafting the submission, and responding to FDA questions — usually takes 3–9 months beforehand. Spectroscopy-based SaMD with a strong predicate may clear faster, while novel applications may face additional information requests that extend the timeline.
The key difference is predicate availability. A 510(k) requires a substantially equivalent predicate device that is already FDA-cleared. De Novo is designed for novel devices with no suitable predicate that present low-to-moderate risk. De Novo is more expensive and time-consuming (12–24 months vs. 6–12 months), but it creates a new device classification — meaning your cleared device becomes the predicate for future competitors. For novel spectroscopy techniques like SERS or terahertz, De Novo is often the only viable pathway.
No — Research Use Only (RUO) software is exempt from FDA premarket review. However, the RUO designation carries strict requirements: the product must be labeled "For Research Use Only. Not for use in diagnostic procedures," and you cannot promote, distribute, or market it for clinical diagnostic use. The FDA actively monitors for RUO products being used clinically, and violations can result in enforcement action. If you plan to transition from RUO to clinical use, begin building your Design History File early.
The FDA has published specific guidance for AI/ML-based SaMD. Key requirements include: a predetermined change control plan describing how the algorithm will be updated post-market, locked vs. adaptive algorithm documentation, clinical validation demonstrating performance across diverse patient populations, and transparency documentation explaining how the AI reaches its conclusions. For spectroscopy AI (e.g., automated Raman tissue classification), you must also validate performance across different instruments, operators, and sample preparation methods.
A PMA submission is the most expensive FDA pathway, typically costing $1–5 million or more. This includes FDA user fees ($425,000+ for large companies, reduced for small businesses), clinical trial costs (often the largest expense), regulatory consulting, software validation documentation, manufacturing process validation, and post-market surveillance setup. For spectroscopy-based Class III devices, clinical trials involving patient samples and reference-method comparisons are usually required.
The International Medical Device Regulators Forum (IMDRF) framework is the globally-adopted system for categorizing SaMD risk. It evaluates two dimensions: the significance of the information provided by the software (inform, diagnose, or treat) and the state of the healthcare condition or situation (non-serious, serious, or critical). These two axes produce a risk matrix with four categories (I through IV) that maps to FDA device classifications. The framework was adopted by the FDA in 2017 and is now the foundation of SaMD regulation worldwide.
Calculate how much your lab could save by automating spectroscopy workflows.
Automatic peak detection and functional group assignment for FTIR spectra.
Identify Raman-active vibrational modes and assign spectral features.
View and analyze your spectral data files interactively.